-+ 0.00%
-+ 0.00%
-+ 0.00%

ME Therapeutics extends option to license NRC CD22 nanobody CAR asset to Feb. 10, 2027

PUBT·10/09/2026 22:37:02
ME Therapeutics extends option to license NRC CD22 nanobody CAR asset to Feb. 10, 2027
  • ME Therapeutics extended its option agreement to license NRC’s nanobody-based CD22 binder for use in CAR therapy.
  • Exercise deadline moved to Feb. 10, 2027.
  • CD22 nanobody remains slated for development within the company’s in vivo CAR program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ME Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261009047275) on October 09, 2026, and is solely responsible for the information contained therein.